Vous trouverez ci-dessous un listing et une fiche descriptive synthétique des projets accompagnés par MATWIN parvenus jusqu’à l’audition devant le Board MATWIN sur les 6 dernières années. La fiche projet détaillée est accessible pour ceux qui ont souhaité la mettre en libre accès.
An autophagy inhibitor with anti-tumoral properties : The company is a clinical-stage company focusing on autophagy, which is mainly used by
cancer cells to grow. Autophagy modulators have been extensively studied in cancer, but none has reached sufficient exposure & efficacy in clinical trials until now...Lire la suite
The ground-breaking microbiome-based biotherapy to potentialize cancer immunotherapy : One of the most striking innovation in oncology recently is the discovery that the microbiome can potentiate the effects of immune checkpoint blockade (ICB) therapies …Lire la suite
The first rationally designed specific TLR3 agonist : We are a preclinical stage company stemming from 20 years of research in innate immunity and TLR3 receptorbiology and modulation…Lire la suite
Clinical Proof of Concept for DNA Repair Biomarkers : The patented DNA Repair assay platform is unique. It mimics the various DNA repair processes on dedicated biochips (multiplex enzymatic DNA repair assays on microsupport). It offers a comprehensive...Lire la suite
Mitochondrial Metabolism Disruptors for Therapeutic Intervention in Oncology : The fundamental design of the company’s drug discovery approach is to create MMD compounds utilising its proprietary NoviChem platform consisting of a mitochondrial targeting group…Lire la suite
CD9P1 as a novel biomarker and therapeutic target for advanced and metastatic solid tumours : New target in immune-modulation to enrich the tumour environment in M2 macrophage. Immunotherapy with Immune Checkpoint Inhibitors (ICIs) has emerged as the most …Lire la suite
Circulating HSP70-exosomes as cancer biomarker : Biomarker that predict clinical outcome, non-invasive approach, minimal pain /risk. The notion of cancer detection by liquid biopsy is a new concept; indeed, many companies are also developing blood-based tests…Lire la suite
Active personalised cancer immunotherapy : A powerful genetic immunisation platform integrating a viral adjuvant and an early immune checkpoint inhibitor (ICI).The first component of the formulation is a variable personalised DNA vector expressing multiple…Lire la suite
CYP Oncology Gene and Immune Therapy : The lead product consists in an optimized gene (named CYP2B6TM-RED), derived from Cytochrome P450 2B6. It is able to convert very efficiently (13 times more efficiently than wild type CYP2B6) a prodrug, cyclophosphamide (CPA)…Lire la suite
Development of small molecules inhibitors of ADP/ATP translocation to mitochondria with anti-tumor activity : Through a rational approach of drug design, the team identified active and specific ANT2 small molecule inhibitors and began their optimization. These molecules display…Lire la suite
Targeting the multidrug transporter Patched potentiates chemotherapy efficiency : The team discovered that the membrane receptor Patched is a new target for cancer treatment. • Patched is overexpressed in many cancers ( lung, breast, prostate, ovary, colon, brain,…Lire la suite
First-in-class PP1 inhibitor – anti-cancer drug candidate : First-in-class selective protein phosphatase 1 inhibitor with an original mechanism of action. The company is developing an innovative small molecule ET-D5, which is a new targeted therapy with an original molecular…Lire la suite
Epigenetic regulations as new therapeutic targets in oncology : In general terms, the team’s innovation is based on the targeting of precise protein/protein complexes from the epigenetic network, that are responsible for defects in the methylation…Lire la suite
Proposition of a CD47/TSP-1 orthosteric antagonist acting at a unique angle at the interface between immunomodulation and anti-angiogenic treatment : The intervention modality concerns a CD47/TSP-1 interaction orthosteric antagonist acting as a competing )…Lire la suite
Cancer vaccine based on the telomerase ribonucleoprotein : A conjugated protein-RNA vaccine (a telomerase ribonucleoprotein comple).There is a strong need to develop an optimized telomerase vaccine, as pointed in 2016 by a key opinion leader from…Lire la suite
HBP-bound doxorubicin: development of a new bone-targeting anticancer therapy to cure pri-mary bone cancer and secondary bone metastases Telomium : The idea behind 12b80 is simple: Decrease doxorubicin systemic distribution and associated cardiotoxicity through…Lire la suite
A therapeutic vaccine candidate for lung cancer based on a proprietary allogeneic cell line of Plasmacytoid Dendritic Cells : XXX*vac: a new class of therapeutic cancer vaccines based on proprietary allogeneic cell line of Plasmacytoid Dendritic Cells (XXX*line), a potent…Lire la suite
Sensing and Treating the IMmune calcium signal in Chronic Lymphocytic Leukemia : Immunotherapy: the originality of the project is based on the discovery of a novel survival pathway in chronic lymphocytic leukaemia (CLL) and the development of specific proprietary monoclonal…Lire la suite
p53 isoforms : a major prognostic marker of the metastasis risk : Highly sensitive and specific prognostic biomarker which targets an original mechanism not yet exploited in the framework ofbiomarkers in oncology (First-in-class).The purpose of the use of a biomarker…Lire la suite
Therapeutic inhibition of GRASP55/JAM-C pathway in Acute Myeloid Leukemiathrough protein/protein interaction inhibition : Protein/protein interaction inhibitor, new pathway. Acute Myeloid Leukemia (AML) is a disease with poor prognosis for which few new…Lire la suite
Human Monocyte-derived Suppressor Cells : HuMoSC are a novel cellular therapeutic approach developed as a prevention of graft rejection in hematologic malignancies with a significant efficiency and further potential application in solid organ.…Lire la suite
Selection of functional aptamers against free molecules in solution for biosensing : The aptamer raised against a given target molecule is engineered in such a way that it switches between an open and a closed conformation upon association to its target, hence…Lire la suite
MIR-K1, a multitarget therapeutic agent for the treatment of liver cancer : A new microRNA with antitumoral properties validated in vitro on 4 hepatoma cell lines and in vivo (chick CAM model).- miR-K1 is more effective in vitro than miR-34a-5p, the microRNA currently tested in….Lire la suite
ERK inhibitors for the treatment of RAF and RAS mutated cancers : The team identified a new original series of small molecules (“NCE” New Chemical Entity) that inhibit ERK kinase activity by using a Fragment-Based approach. After a chemical optimization through a Biotech company…Lire la suite
Define assays for precision medicine in haematological malignancies : We developed methods to define biomarkers/gene signatures to predict sensitivity or resistance of hematologic tumor cells to treatments.Multiple myeloma is a rarely curable malignant disease of…Lire la suite
Theranostic of non-Hodgkin B lymphomas : Predictive marker to anti-CD20 bases therapyPredictive marker to the response to metabolic inhibitors.The incorporation of anti-CD20 (rituximab) coupled with chemotherapy (R-CHOP) in the management…Lire la suite
Neurotensin as novel biological tumor driver :Two anti-neurotensin monoclonal antibodie. Lung cancer is the leading cause of cancer-related deaths in western countries. Two-thirds of patients have reached a metastatic and inoperable state when they meet the oncologist..…Lire la suite
Unique phosphorylated Fas (CD95/TNFSFR6) antibodies : detection of fas phosphorylation for cancer diagnosis and patent stratification : Differential detection of phospho-Fas is achievable using two new monoclonal antibodies (working at least in…Lire la suite
First in class drug candidate XCE853 for humancancer treatment : The company is focusing on the development of its first Drug Candidate XCE853. It has a new Mechanism of action (MOA) and an innovative profile of activity with potent efficacy against different types of…Lire la suite
Guided surgery of cancers by real-time mass spectrometry : SPIDERMASS is an instrument allowing the surgeons in-real time during the surgery to define the tumor margins, determine the existence of potential secondary tumor sites and get information on the potential…Lire la suite
Development of preventing bone anti-metastatic drugs, inhibitors of SK3-basedchannel complex, in targeted cancer therapy : The originality of our project is the development of bone anti-metastatic compounds, acting on cancer cells and based on the discovery of the first…Lire la suite
General approach for targeting solid tumors : Proprietary drug candidates targeting solid tumours (tumour microenvironment, improved penetration, novel target), a ready-to-use platform to generate improved therapeutics for solid tumour. Targeted therapeutics have…Lire la suite
Inhibition using hybrid nucleic acid-lipids as a new therapeutics strategy to restore hormone & chemo-sensivity for the treatment of prostate cancer and other cancers : Target Product Profile (LASO) will be a New Chemical Entity (NCE)..Lire la suite
LLT1 antibodies with new functional properties : The present invention relates to the characterization of monoclonal antibodies that are capable of specifically binding to LLT1,that block the interaction between LLT1 and its receptor CD161 and that have depleting properties….Lire la suite
Preclinical validation of new anti-melanoma compounds : The main research theme of the team is to develop new molecules with anti-melanoma properties. In collaboration with the Chemical Institute of Nice, they identified a new family of active molecules on melanoma…Lire la suite
New nucleoside analogues for the treatment of azacitine-resistant MDS and AML patients : New nucleoside analogues for cancer therapy. This program concerns the development of new nucleotide analogues for the treatment of Azacitidine-resistant MDS and AML patients…Lire la suite
A new class of bioactive molecules targeting cancer (first therapeutic indication : glioblastoma) : PHOST’IN has demonstrated, for GBM and other cancers, in vitro effects of PST 3.1a on tumor proliferation and migration. In vivo studies show a strong reduction of tumor volume…Lire la suite
Anti-glioblastoma peptide : The Anti-Glioblastoma-Peptide is capable:1- to penetrate specifically in all the glioblastoma cells lines and primary cultures that were tested (rat, mouse and human),2- to block microtubule polymerisation,3- to inhibit glioblastoma cell division…Lire la suite
Targeted Therapy of HSP110 for cancer therapy : We propose a new target in cancer therapy: HSP110. Other HSPs are being targeted to sensitize cancer cells to chemotherapy.For instance, many companies are developing inhibitors of HSP90 or HSP27 that are…Lire la suite